1. Prosensa actively working on re-dosing drisapersen and regulatory path forward

    Posted on April 29, 20143:44 pm

    CureDuchenne is pleased to share the following information from Prosensa.   Dear Patient Group Representative, As we continue to receive all of the materials, data and know-how from GSK regarding the drisapersen clinical data set, we continue to actively work on re-dosing and engage with regulators to determine a path forward for drisapersen. We remain Read more »

  2. Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014

    Posted on April 28, 20142:05 pm

    April 28, 2014, 8:32 a.m. EDT CAMBRIDGE, Mass., Apr 28, 2014 (BUSINESS WIRE) — Sarepta Therapeutics, Inc. /quotes/zigman/10874508/delayed/quotes/nls/srpt   SRPT  +1.17% , a developer of innovative  RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014,      beginning at 11:00 a.m. EDT (8:00 a.m. PDT / 5). Chris Garabedian, president Read more »

  3. Sarepta to File Eteplirsen NDA by Year End

    Posted on April 21, 201412:44 pm

    Summary from Seeking Alpha Based on updated guidance from the FDA regarding an  early approval pathway for eteplirsen, Sarepta Therapeutics (SRPT) plans to file an NDA by the end of 2014. The agency provided specific examples of additional  safety and efficacy data for Duchenne muscular dystrophy that would  enhance the acceptability of the NDA. The company will conduct Read more »